3:09 PM Abstract No. 82 Resin vs glass radioembolization: a comparison of survival in patients treated for hepatocellular carcinoma with portal vein thrombosis

Abstract

To compare the survival of patients treated with glass vs resin Yttrium-90 (Y-90) selective internal radiation therapy (SIRT) for hepatocellular carcinoma (HCC) with portal vein thrombosis (PVT). We included all patients treated with Y-90 SIRT for HCC with PVT over a 5 year and 1-month period (18th July 2011 to 9th August 2017). Data was retrospectively collected for survival (days to death or days to last clinical review), Y-90 SIRT carrier-type, Child-Pugh score, age and gender. Categorical variables were analyzed using the Chi-squared test. Continuous variables were analyzed using the Mann-Whitney test. Kaplan-Meier survival curves were used to analyze differences in survival using the Gehan-Breslow-Wilcoxon test. We also recorded whether the patient had whole liver, lobar or segmental SIRT and whether treatment was given in one session or two. Dosimetry was calculated utilizing single compartment MIRD for glass, and partition model for resin. 78 patients satisfied the inclusion criteria. 60 were treated with glass (77%) and 18 were treated with resin (23%). Of those treated with resin SIRT 14 patients were treated with whole liver SIRT; 2 were treated with segmental SIRT; 2 were treated with lobar SIRT. Of those treated with glass, 51 patients were treated with whole liver SIRT; 6 were treated with segmental SIRT; 3 were treated with lobar SIRT. There were no significant differences in Child-Pugh score, age and gender between the two groups (p>0.05). All patients underwent single session SIRT. Median survival by Kaplan-Meier analysis was 171 days for glass and 220 days for resin. Of the patients who died during follow-up, the range of overall survival was 13-1289 days for glass and 26-220 days for resin. There was no significant difference in the survival curves of two groups (p = 0.66). There were no major complications in either group. Results are ongoing. Our findings show no statistically significant difference in survival for patients treated with glass vs resin for Y-90 SIRT in patients with HCC with PVT.